INTRODUCTIONOmeprazole is a potent inhibitor of gastric acid secretion, widely used in the treatment of gastrooesophageal re¯ux disease (GERD) and peptic ulcer disease. 1, 2 Long-term continuous treatment of GERD
SUMMARYBackground: The polymorphic enzyme CYP2C19 is of importance for the metabolism and effects of omeprazole during short-term treatment. Aim: To investigate the relationship between CYP2C19 genotype and the effects of long-term omeprazole treatment. Material and methods: A total of 180 patients with acid related disorders were genotyped for wild type and mutated CYP2C19 alleles by allele-speci®c PCR ampli®cation. Gastrin and chromogranin A were assessed by radioimmunoassays, and pepsinogen I and H. pylori serology were assessed by ELISA methods. Results: In 108 of the patients, who received a single dose of 20 mg omeprazole, there was no difference in gastrin and chromogranin A concentrations between the three CYP2C19 genotypes. In 72 patients on longterm treatment (> 1 year) with 20 mg omeprazole daily, serum gastrin as well as plasma chromogranin A concentrations (mean s.e.) were both about